anti perk Search Results


1 ap  (Proteintech)
96
Proteintech 1 ap
1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pmc11889236__41467_2025_57583_MOESM1_ESM-99-159-156?v=Proteintech
Average 96 stars, based on 1 article reviews
1 ap - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
anti p erk 1 erk 2  (R&D Systems)
90
R&D Systems anti p erk 1 erk 2
Anti P Erk 1 Erk 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/10__1158_slash_1078___0432__ccr___10___1993-89-72-78?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
anti p erk 1 erk 2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
perk  (Rockland Immunochemicals)
93
Rockland Immunochemicals perk
Perk, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pmc03372262-79-5-6?v=Rockland+Immunochemicals
Average 93 stars, based on 1 article reviews
perk - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
phospho erk  (Biosynth Carbosynth)
90
Biosynth Carbosynth phospho erk
Phospho Erk, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pm19854199-65-28-35?v=Biosynth+Carbosynth
Average 90 stars, based on 1 article reviews
phospho erk - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
perk  (Novus Biologicals)
90
Novus Biologicals perk
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
Perk, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/10__1158_slash_1541___7786__mcr___21___0905-72-38-49?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
perk - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
hperk af3999  (R&D Systems)
91
R&D Systems hperk af3999
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
Hperk Af3999, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pmc05041150-117-6-11?v=R%26D+Systems
Average 91 stars, based on 1 article reviews
hperk af3999 - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier
p perk  (Biorbyt)
92
Biorbyt p perk
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
P Perk, supplied by Biorbyt, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pmc11522894__BLOOD_BLD___2023___021991___mmc1-401-47-51?v=Biorbyt
Average 92 stars, based on 1 article reviews
p perk - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
anti perk  (Novus Biologicals)
93
Novus Biologicals anti perk
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
Anti Perk, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pmc11937156-11-0-8?v=Novus+Biologicals
Average 93 stars, based on 1 article reviews
anti perk - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
p erk  (ProSci Incorporated)
94
ProSci Incorporated p erk
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
P Erk, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pm41488470-301-81-80?v=ProSci+Incorporated
Average 94 stars, based on 1 article reviews
p erk - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
nbp1 51 661  (Novus Biologicals)
86
Novus Biologicals nbp1 51 661
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
Nbp1 51 661, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/pmc11937156-11-6-8?v=Novus+Biologicals
Average 86 stars, based on 1 article reviews
nbp1 51 661 - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
perk antibody  (Novus Biologicals)
92
Novus Biologicals perk antibody
Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with <t>indicated</t> <t>antibodies</t> shows the expression of Myc-tagged WT or mutant C9b, ERK activation <t>(pERK),</t> and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.
Perk Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+perk/10__1158_slash_0008___5472__can___21___3155-92-12-14?v=Novus+Biologicals
Average 92 stars, based on 1 article reviews
perk antibody - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

Image Search Results


Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with indicated antibodies shows the expression of Myc-tagged WT or mutant C9b, ERK activation (pERK), and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.

Journal: Molecular Cancer Research

Article Title: Caspase 9b Drives Cellular Transformation, Lung Inflammation, and Lung Tumorigenesis

doi: 10.1158/1541-7786.mcr-21-0905

Figure Lengend Snippet: Figure 6. C9b cooperates with KRAS activation driving lung tumorigenesis. KRASG12D L/þ mice with intratracheal injection (B) of lentiviral particles containing GFP-, WT-, or Mut C9b-Cre(T2a)Luc (A) developed lung tumors (C) at 32 weeks post injection. IHC staining (C) with indicated antibodies shows the expression of Myc-tagged WT or mutant C9b, ERK activation (pERK), and HMGA2 in tumors and the presence of Gr1þ cells in the lung (black arrowheads). Orange arrows point to the clusters of immune cells observed. The percent replacement of normal lung parenchyma by tumor cells based on H&E and pERK signal (n ¼ 12 for GFP, 10 for WT C9b, and 11 for Mut C9b, D), the HMGA2 positivity score (E), and the number of Gr1þ cells per view (20X magnification, G; n ¼ 4 for GFP, 6 for WT C9b and Mut C9b, average of 3 views per mouse for E and G) in each group are shown. F, Metastasis observed in the liver (H&E, 10x magnification) in a mouse with WT C9b expression. Data in D, E and G are means SEM combined from 2 independent intratracheal injection experiments. Adjusted P values are determined by ANOVA Tukey multiple comparison test.

Article Snippet: Mouse organs (lung, liver, spleen, and skin) and tumors were fixed in 10% formalin and embedded in paraffin for histologic and IHC analyses as described (21, 22) using the following primary antibodies: anti-FLAG, -Caspase 9, - IkBa, p65, -pERK, -Myc Tag (Cell Signaling Technology); -SOX2 (Sigma); -Gr1 (Ly6G/6C), IL6 (Novus Biologicals); -HMGA2 (ThermoFisher, Waltham, MA); -p63, and -Synaptophysin (Santa Cruz Biotechnology).

Techniques: Activation Assay, Injection, Immunohistochemistry, Expressing, Mutagenesis, Comparison